Previous 10 | Next 10 |
2023-12-08 13:13:33 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Biomea stock tumbles in wake of Phase 2 data for diabetes drug Biomea Fusion spikes after mid-stage data for diabetes candidate Seeking Alpha’s ...
2023-12-08 12:48:05 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Biomea Fusion spikes after mid-stage data for diabetes candidate Seeking Alpha’s Quant Rating on Biomea Fusion Historical earnings data for Biom...
2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219, participants in the 100 mg QD (without food) cohort saw an improved placebo adjusted mean re...
2023-12-07 12:09:15 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Seeking Alpha’s Quant Rating on Biomea Fusion Historical earnings data for Biomea Fusion Financial information for Biomea Fusion For fur...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes In a poster presentation on Thursday, Dec. 7 th at 6:30pm and an oral presentation on Friday, Dec. 8 th at 7:30pm, Biomea to present ne...
BMF-219 is a novel investigational covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes Health Canada has cleared the initiation of COVALENT-112, a Phase II clinical trial of BMF-219 in adults living with type 1 diabetes (T1D), foll...
2023-12-04 12:22:42 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; SilverSun Technologies Inc (NASDAQ: SSNT), EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), Alterity Therap...
2023-11-29 17:30:44 ET Gainers: Nutanix ( NTNX ) +5% . Titan Machinery ( TITN ) +4% . Biomea Fusion ( BMEA ) +4% . Intuitive Machines ( LUNR ) +4% . Ocular Therapeutix ( OCUL ) +4% . Losers: Credo Technology Group (...
2023-11-29 13:02:14 ET More on mid-day movers stocks. Sonder Holdings Inc. (SOND) Q3 2023 Earnings Call Transcript Fusion Fuel receives purchase order from Portuguese energy company for 1.25 MW electrolyzer facility Fusion Fuel Green receives Nasdaq notice regarding ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...